Literature DB >> 3375987

Surgical therapy of localized abdominal non-Hodgkin's lymphomas.

S J Mentzer1, R T Osteen, T N Pappas, D S Rosenthal, G P Canellos, R E Wilson.   

Abstract

Non-Hodgkin's lymphomas may involve a variety of abdominal organs, including the liver, spleen, gastrointestinal tract, and retroperitoneum. The number of organs potentially involved and the noncontiguous mode of spread make non-Hodgkin's lymphoma a difficult tumor to evaluate at the time of laparotomy. To clarify the surgical management of patients with this tumor, we retrospectively reviewed the medical records of 202 patients with histologically proven abdominal lymphomas. Within this group, 36 patients underwent laparotomy before they had chemotherapy or radiation therapy. Ten patients were explored to establish a histologic diagnosis of lymphoma. The remaining 26 patients underwent laparotomy because of presumed benign disease. Twenty patients were found to have localized disease at laparotomy. Patients with localized disease demonstrated significantly better survival than patients with extranodal and nodal involvement (p less than 0.05). Four patients with local resection received no adjuvant therapy and were free of disease a median of 50 months after surgery.

Entities:  

Mesh:

Year:  1988        PMID: 3375987

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

Review 1.  Update on gastric lymphoma.

Authors:  C R Thomas
Journal:  J Natl Med Assoc       Date:  1991-08       Impact factor: 1.798

2.  Long-term follow-up after curative surgery for early gastric lymphoma.

Authors:  D L Bartlett; M S Karpeh; D A Filippa; M F Brennan
Journal:  Ann Surg       Date:  1996-01       Impact factor: 12.969

3.  Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases.

Authors:  J E Morton; M J Leyland; G Vaughan Hudson; B Vaughan Hudson; L Anderson; M H Bennett; K A MacLennan
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.